The glycoprotein IIb/IIIa inhibitor wars: An update

Journal of the American College of Cardiology

Volumn 56, Issue 6, 2010, Pages 476-478

  Berger, Peter B ^a  

^a GEISINGER MEDICAL CENTER   (United States)

Author keywords

glycoprotein IIb IIIa inhibitors; primary percutaneous coronary intervention; ST segment elevation myocardial infarction

Indexed keywords

ABCIXIMAB; CLOPIDOGREL; CREATINE KINASE; CREATINE KINASE MB; EPTIFIBATIDE; PRASUGREL; THIENOPYRIDINE DERIVATIVE; TIROFIBAN; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR;

ACUTE HEART INFARCTION; BOLUS INJECTION; CLINICAL EFFECTIVENESS; CREATINE KINASE BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; ELECTROCARDIOGRAPHY; HEALTH CARE POLICY; HUMAN; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PUBLIC OPINION; RECEPTOR OCCUPANCY; ST SEGMENT ELEVATION; SWEDEN; THORAX PAIN; THROMBOCYTE AGGREGATION; THROMBOCYTE TRANSFUSION; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PROCEDURES; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TREATMENT OUTCOME;

EID: 77955479798     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.01.064     Document Type: Editorial

References (18)

1. D.R. Holmes, and P.B. Berger Editorial: troponisms, necrossettes, enzyme leaks, CPK bumps, and infarctlets What's behind this new lexicon and what does it add? Circulation 104 2001 627 629
2. D. Kong, V. Hasselblad, and R. Harrington Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions Am J Cardiol 92 2003 651 655
3. M.J. Ricciardi, E. Wu, and C.J. Davidson Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation Circulation 103 2001 2780 2783
4. K.A. Anderson, R.M. Califf, and G.W. Stone Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention J Am Coll Cardiol 37 2001 2059 2065
5. F.R. Curtiss, and K.A. Fairman Pharmacy benefit spending poised to increase for antithrombotic drug therapy-prasugrel versus clopidogrel J Manag Care Pharm 15 2009 414 416
6. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
7. D.J. Schneider, and A. Aggarwal Development of glycoprotein IIb-IIIa antagonists: translation from pharmacodynamic effect to clinical benefit Expert Rev Cardiovasc Ther 2 2004 903 913
8. The GUSTO-IV ACS Investigators Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomized trial Lancet 357 2001 1915 1924
9. Y.F. Li, F. Spencer, and R. Becker Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (αIIb/β3) receptor-directed platelet inhibition Am Heart J 142 2001 204 210
10. E.J. Topol, D.J. Moliterno, and H.C. Herrmann Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization N Engl J Med 344 2001 1888 1894
11. M. Valgimigli, G. Biondi-Zoccai, and M. Tebaldi Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials Eur Heart J 31 2010 35 49
12. H. Gurm, U. Tamhane, and P. Meier A comparison of abciximab and small molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials Circ Cardiovasc Intervent 2 2009 230 236
13. G. De Luca, G. Ucci, and E. Cassetti Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis J Am Coll Cardiol 53 2009 1668 1673
14. U. Zeymer, A. Margenet, and M. Haude Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI trial J Am Coll Cardiol 56 2010 463 469
15. A. kerblom, S.K. James, and M. Koutouzis Eptifibatide is non-inferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) J Am Coll Cardiol 56 2010 470 475
16. U. Stenestrand, L. Wallentin Swedish Register of Cardiac Intensive Care (RIKS-HIA) Early statin treatment following acute myocardial infarction and 1-year survival JAMA 285 2001 430 436
17. F.G. Kushner, M. Hand, and S.C. Smith Jr. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 54 2009 2205 2241
18. S. Saul Gimme an Rx! Cheerleaders pep up drug sales November 28, 2005 The New York Times